CD34 and chronic graft versus host disease: Since higher CD3+ cell doses were independently associated with the risk of moderate to severe chronic GVHD, and there was a weak association between CD34+ and CD3+ cell counts, cell counts other than CD34+ should be considered as well for optimal treatment outcomes.